Thousands of women with severe postnatal depression are set to benefit from the UK’s first ever drug to treat the condition.
Experts have long been unsure exactly what triggers postnatal depression despite the fact that one in ten women are affected within a year of giving birth.
Until now, women have typically been prescribed talking therapies or antidepressants.
But in a move hailed as a ‘breakthrough’ for women’s health, the UK medicines regulator has approved a 14-day pill to treat moderate or severe postnatal depression.
The drug, known as zuranolone and sold as Zurzuvae, works by boosting the brain’s calming signals, helping to restore hormonal imbalances that happen during pregnancy and childbirth.
Unlike existing treatments, which can take weeks to take effect, Zurzuvae has been proven to start working within just three days.
Clinical trials, critical to the drug getting approved, also showed the effects of a 50mg dose of the drug lasted for 45 days.
Even at a lower 30mg dose, results were similar.
In a move hailed as a ‘breakthrough’ for women’s health, the UK medicines regulator has approved a 14-day pill to treat moderate or severe postnatal depression
Maternal depression and anxiety are relatively common after giving birth, often prompted by major physical and emotional changes
Like all medications, it is not without its side effects. Commonly reported effects included extreme drowsiness—known as somnolence—dizziness and fatigue.
As such, patients are advised to avoid driving for at least 12 hours after each dose.
But no reports of serious effects such as weight gain or sexual dysfunction, were logged.
Responding to the Medicines and Healthcare products Regulatory Agency’s (MHRA) approval of the drug, manufacturer Biogen’s general manager Kylie Bromley, said: ‘This is an important first step in our journey to help address the needs of women experiencing post-natal depression in the UK.
‘We are committed to working with NICE, the SMC and other stakeholders to ensure this treatment becomes accessible to all women who need it.
‘This approval reflects our ongoing drive to make breakthroughs happen in the science of mental health.
‘We are proud to offer a new treatment option developed to help positively impact the lives of women and their families.’
Dr Mano Manoharan, a consultant perinatal psychiatrist, also said: ‘Postnatal depression impacts not only mothers but also infants and families. Holistic, evidence-based treatments are vital.
Chrissy Teigen has previously opened up about her heartbreaking experience, telling Glamour: ‘What basically everyone around me but me knew up until December was this: I have postpartum depression. How can I feel this way when everything is so great?’
‘The introduction of zuranolone offers a fast-acting, targeted breakthrough to support women swiftly and compassionately.’
Postnatal depression is a serious condition that causes intense feelings of sadness, anxiety and exhaustion that usually begin two to three days after birth and can last for months—severely impacting a mother’s ability to care for herself and her baby.
It is different from the ‘baby blues’, which many mothers experience whilst they struggle to adjust to the stress and hormonal changes that come with having a child.
Common symptoms include insomnia, loss of appetite, intense irritability and difficulty bonding with the baby.
Over the years, celebrities including Gwenyth Paltrow, Chrissy Teigen, Ashley Graham and even Kate Middleton have shared their experience of postnatal depression.
Annually, it is believed around 23.8 million women worldwide will experience the condition.
This article was originally published by a www.dailymail.co.uk . Read the Original article here. .